Gelatinized core liposomes: A new Trojan horse for the development of a novel timolol maleate glaucoma medication

Hathout, Rania M.; Gad, Heba A.; Abdel-Hafez, Salma M.; Nasser, Nayera; Khalil, Noha; Ateyya, Toka; Amr, Alaa; Yasser, Nesreen; Nasr, Sandy; Metwally, Abdelkader A.

doi:10.1016/j.ijpharm.2018.12.015

Cited by 51 publications

(21 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This implies an affirmative role of ceramide-loaded liposomes for treating anterior segment ocular inflammation (Sun et al, 2008) (Table 4). Hathout et al (2019) showed that timolol maleate gelatinized liposome treatment resulted in lowering the IOP when evaluated in vivo on the eyes of glaucomatous rabbits. Song et al developed a tocopheryl polyethylene glycol succinate (TPGS) modified nanoliposome ocular drug-delivery system for brinzolamide for the treatment of glaucoma.…”

Section: Novel Ocular Drug-delivery Technologies Colloidal Nanocarriementioning

confidence: 99%

Ocular Drug Delivery: Present Innovations and Future Challenges

Gote

Sikder

Sicotte

et al. 2019

J Pharmacol Exp Ther

269

209

View full text Add to dashboard Cite

Ocular drug delivery has always been a challenge for ophthalmologists and drug-delivery scientists due to the presence of various anatomic and physiologic barriers. Inimitable static and dynamic ocular barriers not only exclude the entry of xenobiotics but also discourage the active absorption of therapeutic agents. Designing an ideal delivery scheme should include enhanced drug bioavailability and controlled release of drug at the site of action, which can overcome various ocular barriers. Conventional ophthalmic medications include the use of topical eye drops and intravitreal injections of anti-vascular endothelial growth factor agent for treatment of anterior and posterior segment disorders, respectively. Current inventions for anterior ocular segment disorders such as punctum plugs, ocular implants, drug-eluting contact lenses, and ocular iontophoresis represent state-of-the-art inventions for sustained and controlled drug release. Parallel efforts for ocular drug delivery technologies for back of the eye disorders have resulted in the approval of various intravitreal implants. Novel drug-delivery technologies, including nanoparticles, nanomicelles, dendrimers, microneedles, liposomes, and nanowafers, are increasingly studied for anterior and posterior disorders. To achieve patient compliance for back of the eye disorders, novel approaches for noninvasive delivery of potent therapeutic agents are on the rise. In this review article, we discuss past successes, present inventions, and future challenges in ocular drug-delivery technologies. This expert opinion also discusses the future challenges for ocular drug-delivery systems and the clinical translatable potential of nanotechnology from benchtop to bedside.

show abstract

Section: Novel Ocular Drug-delivery Technologies Colloidal Nanocarriementioning

confidence: 99%

Ocular Drug Delivery: Present Innovations and Future Challenges

Gote

Sikder

Sicotte

et al. 2019

J Pharmacol Exp Ther

269

209

View full text Add to dashboard Cite

show abstract

“…Brb loaded liposomes were formulated adapting the thin-film hydration method [ 21 ]. Full-factorial design was implemented to evaluate the impact of different variables on the properties of the prepared vesicles.…”

Section: Methodsmentioning

confidence: 99%

Optimization of Hyaluronate-Based Liposomes to Augment the Oral Delivery and the Bioavailability of Berberine

et al. 2021

Self Cite

View full text Add to dashboard Cite

Various perspectives had been utilized to enhance the poor intestinal permeability and bioavailability of drugs with low water solubility. Berberine (Brb) is a unique molecule that possesses multiple therapeutic activities such as antimicrobial, anti-inflammatory, antioxidant and anti-hyperglycemic effects. To improve Brb permeability and bioavailability, this study presents a newly developed formulation, namely Brb hyaluronate-based liposomes, prepared by using film hydration method and characterized by dynamic light scattering measurements, entrapment efficiency percentage (EE%), transmission electron microscope (TEM), in vitro drug release and physical stability. The bioavailability of the selected formulations was assessed in vivo after oral administration to rats. The results revealed an enhanced effect of hyaluronic acid on the entrapment efficiency, reaching 78.1 ± 0.1% with mean size 520.7 ± 19.9 nm. Sustained release of Brb was recorded up to 24 h in comparison to Brb solution. Physical stability was maintained for three months at refrigeration temperature. Results of pharmacokinetics studies indicated the potential of the liposomal formulation to increase the oral bioavailability of Brb and to accelerate its entry into the bloodstream. The obtained results are accredited to the lipophilic nature of the prepared system, resembling the structural features of bio-membrane, in addition to their small size that enhances intestinal penetration.

show abstract

“…Some researchers have investigated gelatin A as a potential excipient in drug delivery systems for timolol maleate. In an initial study, liposomes with a gelatinized core were developed and found to be safe, biocompatible with ocular tissues, stable, and achieved sustained release of the drug [ 130 ]. Other researchers created gelatin nanoparticles.…”

Section: Excipients Used In Ocular Formulations For Modified Drug Deliverymentioning

confidence: 99%

Recent Advances in the Excipients Used for Modified Ocular Drug Delivery

et al. 2021

View full text Add to dashboard Cite

In ocular drug delivery, maintaining an efficient concentration of the drug in the target area for a sufficient period of time is a challenging task. There is a pressing need for the development of effective strategies for drug delivery to the eye using recent advances in material sciences and novel approaches to drug delivery. This review summarizes the important aspects of ocular drug delivery and the factors affecting drug absorption in the eye including encapsulating excipients (chitosan, hyaluronic acid, poloxamer, PLGA, PVCL-PVA-PEG, cetalkonium chloride, and gelatin) for modified drug delivery.

show abstract

Gelatinized core liposomes: A new Trojan horse for the development of a novel timolol maleate glaucoma medication

Cited by 51 publications

References 39 publications

Ocular Drug Delivery: Present Innovations and Future Challenges

Ocular Drug Delivery: Present Innovations and Future Challenges

Optimization of Hyaluronate-Based Liposomes to Augment the Oral Delivery and the Bioavailability of Berberine

Recent Advances in the Excipients Used for Modified Ocular Drug Delivery

Contact Info

Product

Resources

About